AZN - AstraZeneca Nirsevimab Data And Other News: The Good Bad And Ugly Of Biopharma
AstraZeneca reports positive data for nirsevimab
AstraZeneca (AZN) announced positive data for nirsevimab for the passive immunization against respiratory syncytial virus ((RSV)) infections in healthy preterm infants. The data showed that the treatment was able to provide favorable results. AstraZeneca is collaborating with Sanofi (SNY) for the development of this drug candidate.
The primary endpoint of the trial was related to the reduction of medically attended RSV lower respiratory tract infection (LRTI) compared to placebo through day 150 after dosing. The drug candidate showed statistically significant results with a 70.1 percent reduction in